Seres Therapeutics, Inc. (MCRB): John G. Aunins , Chief Technology Officer & EVP of Seres Therapeutics, Inc. sold 9,390 shares on Jun 27, 2016. The Insider selling transaction was reported by the company on Jun 29, 2016 to the Securities and Exchange Commission. The shares were sold at $27.23 per share for a total value of $255,689.70 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 29, 2016, Eric D. Shaff (CFO and EVP) sold 5,001 shares at $28.42 per share price.On Jun 6, 2016, Roger Pomerantz (President and CEO) sold 74,049 shares at $32.39 per share price.Also, On Jun 6, 2016, David N Cook (Chief Scientific Officer & EVP) sold 8,000 shares at $31.00 per share price.On Jun 3, 2016, John G. Aunins (Chief Technology Officer & EVP) sold 14,015 shares at $30.30 per share price.
Shares of Seres Therapeutics Inc (MCRB) ended Monday, Jun 27, 2016 session in red amid volatile trading. The shares closed down -1.23 points or -4.35% at $27.06 with 3,16,184 shares getting traded. Post opening the session at $28, the shares hit an intraday low of $25.87 and an intraday high of $28 and the price vacillated in this range throughout the day. The company has a market cap of $1,069 M and the number of outstanding shares has been calculated to be 3,95,19,842 shares. The 52-week high of Seres Therapeutics Inc is $52 and the 52-week low is $21.12.
Seres Therapeutics Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a range of biological drugs Ecobiotic microbiome therapeutics. It is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome in the human body. Its products include SER-109 which is designed to prevent further recurrences of Clostridium difficile infection (CDI) a debilitating infection of the colon; SER-109; SER-262 and SER-155. It’s SER-262 is a multi-strain Ecobiotic microbiome therapeutic to be used following antibiotic treatment of primary CDI to prevent an initial recurrence of CDI. The Company is developing SER-287 to treat ulcerative colitis. It is developing SER-155 which is an Ecobiotic microbiome therapeutic to treat enteric pathogens.